Payment overview · 2025
General Payments
$714.38
31 reported records · 10 companies
Healthcare provider profile · identity verified
Jonathan Aronbayev, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · BRIARWOOD, NY · NPI 1750318721
Verified facts
What the public records show
CMS Open Payments records show Jonathan Aronbayev, M.D received $714.38 in general payments during 2025 across 31 reported records.
ABBVIE INC. accounted for 44.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Ozempic, Prolia, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 290 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $314.23 | 44.0% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $92.41 | 12.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $82.70 | 11.6% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $75.67 | 10.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $40.43 | 5.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.01 | 3.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.53 | 3.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.66 | 3.2% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.03 | 2.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.71 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $714.38 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $261.00 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $96.47 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $92.41 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $82.70 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $60.48 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $46.70 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40.43 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $28.97 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.82 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $26.41 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $26.41 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 59 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 216 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 290 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 123 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
290 | 37 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
86 | 11 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
123 | 14 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
61 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
216 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
194 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 591 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 360 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 323 | 53 |
| Linzess | Linaclotide | 290 | 37 |
| Metformin Hcl | Metformin Hcl | 269 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 262 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 261 | 44 |
| Januvia | Sitagliptin Phosphate | 238 | 26 |
| Farxiga | Dapagliflozin Propanediol | 216 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 215 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 214 | 37 |
| Losartan Potassium | Losartan Potassium | 214 | 44 |
| Omeprazole | Omeprazole | 199 | 33 |
| Eliquis | Apixaban | 194 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 187 | 28 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 184 | 24 |
| Famotidine | Famotidine | 173 | 34 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 143 | 36 |
| Ezetimibe | Ezetimibe | 141 | 23 |
| Carvedilol | Carvedilol | 137 | 18 |
| Gabapentin | Gabapentin | 137 | 29 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 131 | 18 |
| Vascepa | Icosapent Ethyl | 128 | 15 |
| Zenpep | Lipase/Protease/Amylase | 123 | 14 |
| Dexilant | Dexlansoprazole | 118 | 15 |
| Ozempic | Semaglutide | 109 | 22 |
| Jardiance | Empagliflozin | 108 | 21 |
| Glipizide | Glipizide | 107 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 20 |
| Furosemide | Furosemide | 103 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 20 |
| Glimepiride | Glimepiride | 94 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 14 |
| Sertraline Hcl | Sertraline Hcl | 90 | 14 |
| Synthroid | Levothyroxine Sodium | 86 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 32 |
| Metformin Hcl Er | Metformin Hcl | 76 | suppressed |
| Allopurinol | Allopurinol | 75 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 71 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 11 |
| Trazodone Hcl | Trazodone Hcl | 70 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | suppressed |
| Valsartan | Valsartan | 69 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 68 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 67 | 13 |
| Torsemide | Torsemide | 64 | 14 |
| Lisinopril | Lisinopril | 62 | 11 |
| Meloxicam | Meloxicam | 62 | 19 |
| Myrbetriq | Mirabegron | 61 | 11 |
| Repatha Sureclick | Evolocumab | 60 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 60 | 11 |
| Creon | Lipase/Protease/Amylase | 59 | 12 |
| Repaglinide | Repaglinide | 58 | suppressed |
| Felodipine Er | Felodipine | 55 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 12 |
| Spironolactone | Spironolactone | 53 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 52 | 12 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 47 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 46 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 46 | 23 |
| Atenolol | Atenolol | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 34 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | 12 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 37 |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 39 | 27 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Nexium | Esomeprazole Magnesium | 39 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 38 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Ranolazine Er | Ranolazine | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 33 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 32 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 31 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Invokana | Canagliflozin | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 30 | 13 |
| Sotalol | Sotalol Hcl | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 17 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 12 |
| Meclizine Hcl | Meclizine Hcl | 28 | 15 |
| Lidocaine | Lidocaine | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Latuda | Lurasidone Hcl | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | 14 |
| Dutasteride | Dutasteride | 25 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Livalo | Pitavastatin Calcium | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 23 | suppressed |
| Proctozone-Hc | Hydrocortisone | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Cyclosporine | Cyclosporine | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 22 | suppressed |
| Prednisone | Prednisone | 22 | 20 |
| Eplerenone | Eplerenone | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 17 | suppressed |
| Flomax | Tamsulosin Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Crestor | Rosuvastatin Calcium | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Tribenzor | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Jublia | Efinaconazole | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Toprol Xl | Metoprolol Succinate | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Diovan Hct | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Norvasc | Amlodipine Besylate | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Plavix | Clopidogrel Bisulfate | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Avodart | Dutasteride | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Proscar | Finasteride | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Denavir | Penciclovir | 11 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Lasix | Furosemide | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $714.38 · 31 records | ABBVIE INC. | CAMZYOS, CREON, EVENITY, FARXIGA, LINZESS, Ozempic, PROLIA, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VOWST, VRAYLAR, Veozah, XIFAXAN, ZENPEP, ZTLido | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error